Search
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalserotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible proposal that noradrenaline plays an
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsEthylhexyl methoxycrylene
go.drugbank.com/drugs/DB11226ApprovedIt currently enjoys regional approvals in Canada, the EU, and the US [L2847].
Patisiran
go.drugbank.com/drugs/DB14582ApprovedPatisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis . It is marketed as Onpattro which is formulated as patisiran within a liposome...
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalThis can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. … In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersSynonyms: (−)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinolTick-borne encephalitis vaccine (whole virus, inactivated)
go.drugbank.com/drugs/DB16611ApprovedInvestigational[A237520] Due to a paucity of effective safe and effective acute therapeutic agents, vaccination remains the most important defence against TBE in endemic areas. … [A237505, A237520] While some patients recover fully following neurological TBE, neurological sequelae can last for years and rare chronic forms of the disease have also been noted.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigationalmineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due … [A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesRitlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalRitlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: 2-propen-1-one, 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-D)pyrimidin-4-ylamino)-1-piperidinyl)-Niclosamide
go.drugbank.com/drugs/DB06803ApprovedInvestigationalVet approvedNiclosamide is an antihelminthic used for the treatment of tapeworm infections. … They are an even greater problem in domestic animals. Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsAntihemophilic factor human
go.drugbank.com/drugs/DB13192ApprovedInvestigationalextended half-life compared with conventional factor VIII due to conjugation to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein [A31551]. … Endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as a co-factor to Factor IX.
Mixtures: HAEMATE P 1000/2400 IU I.V. ENJEKSİYON/İNFÜZYON İÇİN TOZ VE ÇÖZÜCÜ, HAEMATE P 500/1200 IU I.V. ENJEKSİYON/İNFÜZYON İÇİN TOZ VE ÇÖZÜCÜProducts: Monoclate-P, Haemate P 250 I.E. FVIII / 600 I.E. VWF Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung. Haemate P 500 I.E. FVIII / 1200 I.E.